HIV/AIDS Clinical Care: Archives

SUMMARY AND COMMENT

Which HIV Test Is Best in High-Incidence Groups?

• July 27, 2009
• Carlos del Rio, MD

In a study of specimens from Seattle-area MSM, a rapid antibody test detected HIV infection less well than did either enzyme immunoassay antibody testing or nucleic-acid amplification testing.

• Reviewing:
• Stekler JD et al., Clin Infect Dis 2009 Aug 1; 49:444

SUMMARY AND COMMENT

HIV Resistance Testing Is Associated with Improved Survival

• July 27, 2009
• Paul E. Sax, MD

HIV outpatients who underwent resistance testing were less likely to die than their untested counterparts during about 3 years of follow-up, but no single factor is likely to explain this observational finding.

• Reviewing:
• Palella FJ Jr et al., Ann Intern Med 2009 Jul 21; 151:73 Volberding P., Ann Intern Med 2009 Jul 21; 151:135

SUMMARY AND COMMENT

How Effective Is ART for AIDS-Related Kaposi Sarcoma?

• July 20, 2009
• Joan Goldberg, MD

In a British cohort study, HIV-infected patients with Kaposi sarcoma had an excellent survival rate, and most were treated effectively with antiretroviral therapy alone.

• Reviewing:
• Bower M et al., AIDS 2009 Jun 20

SUMMARY AND COMMENT

Does Abacavir/3TC Still Have a Role in First-Line Therapy for HIV?Free

• July 20, 2009
• Charles B. Hicks, MD

In the HEAT randomized trial, abacavir/3TC was noninferior to tenofovir/FTC when each was used in combination with lopinavir/r in treatment-naive patients, regardless of pretreatment viral load.

• Reviewing:
• Smith KY et al., AIDS 2009 Jun 17

SUMMARY AND COMMENT

Interleukin-2: A Molecule Looking for a Job in the HIV Sector

• July 20, 2009
• Abigail Zuger, MD

Interleukin-2 injections can allow us to postpone the initiation of antiretroviral therapy . . . but do we really want to do that?

• Reviewing:
• Molina J-M et al., J Infect Dis 2009 Jul 15; 200:206 Kuritzkes DR., J Infect Dis 2009 Jul 15; 200:164

SUMMARY AND COMMENT

HPV Prevalence Before and After Women Start ART

• July 20, 2009
• Sonia Nagy Chimienti, MD

As HIV-infected women started ART and their CD4-cell counts increased, the prevalence of HPV — and of high-risk HPV specifically — declined through 96 weeks of follow-up.

• Reviewing:
• Fife KH et al., J Acquir Immune Defic Syndr 2009 Jul 1; 51:274

SUMMARY AND COMMENT

Another Benefit to Starting ART Early: Lower Risk for ResistanceFree

• July 13, 2009
• Paul E. Sax, MD

Among patients who experienced virologic rebound in this observational cohort study, risk for resistance was decreased in those who initiated ART at CD4 counts >350 cells/mm³.

• Reviewing:
• Uy J et al., J Acquir Immune Defic Syndr 2009 Aug; 51:450

SUMMARY AND COMMENT

Failure on First-Line Lopinavir/r Monotherapy: High Rates of PI Resistance

• July 13, 2009
• Keith Henry, MD

Results from the MONARK trial do not support lopinavir/r monotherapy as first-line treatment for HIV infection, because it was both less effective and more likely to cause major PI resistance than triple therapy with lopinavir/r, AZT, and 3TC.

• Reviewing:
• Delaugerre C et al., Antimicrob Agents Chemother 2009 Jul; 53:2934

SUMMARY AND COMMENT

Cryptococcal Meningitis and IRIS: The Cost of Waiting

• July 6, 2009
• Rajesh T. Gandhi, MD

Delaying ART because of concern about immune reconstitution inflammatory syndrome might be fatal.

• Reviewing:
• Bicanic T et al., J Acquir Immune Defic Syndr 2009 Jun 1; 51:130

ANTIRETROVIRAL ROUNDS

Should We Mess with Success?Free

• July 6, 2009

Experts grapple with whether to change the regimens for three patients who had undetectable viral loads and normal or near-normal CD4-cell counts and were tolerating their treatments well.